Literature DB >> 16534121

Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia.

M C F Gerrits1, E M J Foncke, R de Haan, K Hedrich, Y L C van de Leemput, F Baas, L J Ozelius, J D Speelman, C Klein, M A J Tijssen.   

Abstract

The epsilon-sarcoglycan (SGCE) gene is an important cause of myoclonus-dystonia (M-D), although the majority of cases with an M-D phenotype test negative. Seven of 31 patients with the M-D phenotype carried a mutation in the SGCE gene. Positive family history and truncal myoclonus were independent prognostic factors. Early disease onset, onset with both myoclonus and dystonia, and axial dystonia were detected significantly more often in the mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534121     DOI: 10.1212/01.wnl.0000201192.66467.a3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  The clinical approach to movement disorders.

Authors:  Wilson F Abdo; Bart P C van de Warrenburg; David J Burn; Niall P Quinn; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2010-01       Impact factor: 42.937

2.  The intermuscular 3-7 Hz drive is not affected by distal proprioceptive input in myoclonus-dystonia.

Authors:  J N van der Meer; A C Schouten; L J Bour; E de Vlugt; A F van Rootselaar; F C T van der Helm; M A J Tijssen
Journal:  Exp Brain Res       Date:  2010-02-16       Impact factor: 1.972

3.  Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation.

Authors:  Kristoffer Haugarvoll; Charalampos Tzoulis; Gia T Tran; Bjørn Karlsen; Bernt A Engelsen; Per M Knappskog; Laurence A Bindoff
Journal:  J Neurol       Date:  2013-12-03       Impact factor: 4.849

4.  Reduced striatal D2 receptor binding in myoclonus-dystonia.

Authors:  R J Beukers; J Booij; N Weisscher; F Zijlstra; T A M J van Amelsvoort; M A J Tijssen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-22       Impact factor: 9.236

5.  Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles.

Authors:  J M Hagenah; I R König; B Becker; R Hilker; M Kasten; K Hedrich; P P Pramstaller; C Klein; G Seidel
Journal:  J Neurol       Date:  2007-10-15       Impact factor: 4.849

Review 6.  Update on pediatric dystonias: etiology, epidemiology, and management.

Authors:  Emilio Fernández-Alvarez; Nardo Nardocci
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-04-11

7.  Writer's cramp as a presentation of L-2-hydroxyglutaric aciduria.

Authors:  Pichet Termsarasab; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2014-12-11

8.  Distribution and Coexistence of Myoclonus and Dystonia as Clinical Predictors of SGCE Mutation Status: A Pilot Study.

Authors:  Rodi Zutt; Joke M Dijk; Kathryn J Peall; Hans Speelman; Yasmine E M Dreissen; Maria Fiorella Contarino; Marina A J Tijssen
Journal:  Front Neurol       Date:  2016-05-13       Impact factor: 4.003

9.  SGCE mutations cause psychiatric disorders: clinical and genetic characterization.

Authors:  Kathryn J Peall; Daniel J Smith; Manju A Kurian; Mark Wardle; Adrian J Waite; Tammy Hedderly; Jean-Pierre Lin; Martin Smith; Alan Whone; Hardev Pall; Cathy White; Andrew Lux; Philip Jardine; Narinder Bajaj; Bryan Lynch; George Kirov; Sean O'Riordan; Michael Samuel; Timothy Lynch; Mary D King; Patrick F Chinnery; Thomas T Warner; Derek J Blake; Michael J Owen; Huw R Morris
Journal:  Brain       Date:  2013-01       Impact factor: 13.501

10.  SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype.

Authors:  Kathryn J Peall; Manju A Kurian; Mark Wardle; Adrian J Waite; Tammy Hedderly; Jean-Pierre Lin; Martin Smith; Alan Whone; Hardev Pall; Cathy White; Andrew Lux; Philip E Jardine; Bryan Lynch; George Kirov; Sean O'Riordan; Michael Samuel; Timothy Lynch; Mary D King; Patrick F Chinnery; Thomas T Warner; Derek J Blake; Michael J Owen; Huw R Morris
Journal:  J Neurol       Date:  2014-09-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.